• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Recursion Pharmaceuticals Inc.

    4/28/25 4:03:25 PM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RXRX alert in real time by email
    DEFA14A 1 rxrx_proxystatement2025-ad.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    (Rule 14a-101)
    INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☒Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12

    Recursion Pharmaceuticals, Inc.
    (Exact name of registrant as specified in its charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant) 

    Payment of Filing Fee (Check the appropriate box):
    ☒No fee required.
    ☐Fee paid previously with preliminary materials.
    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





    notice_pagex1.jpg



    notice_pagex2.jpg

    Get the next $RXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXRX

    DatePrice TargetRatingAnalyst
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    9/21/2021$37.00Buy
    Berenberg
    8/16/2021$33.00 → $30.00Outperform
    SVB Leerink
    More analyst ratings

    $RXRX
    SEC Filings

    See more
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      6/18/25 4:22:09 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      6/10/25 6:04:56 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Recursion Pharmaceuticals Inc.

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/9/25 5:27:47 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care